of Blood, Krause et all review the structure and biology of CD34, accompanied by a cover photograph of a flow cytometric experiment with PE-CY5-conjugated monoclonal antibody (MoAb). PE-CY5 tandem (tricolor) staining is nowadays extremely popular for three-color flow cytometric analyses.' However, recent findings in our laboratory showing effective binding of PE-CY5 conjugates to the human class I IgG receptor (CD64) may limit the broad use of this dye for flow cytometry.
to methodology as recommended by the suppliers. We first analyzed staining of isolated monocytes and neutrophils (PMN) from normal donors and PMN from patients treated with granulocyte colonystimulating factor (G-CSF) in vivo. Surprisingly, both monocytes ( Fig Id) and G-CSF-PMN (Fig Ib) exhibited bright staining with PE-CY5-conjugated MoAb directed to T-and B-cell antigens, in contrast to normal PMN (Fig 1 a) . PMN express high levels of FcyRIl (CD32) and FcyRllI (CD16), whereas monocytes and G-CSF PMN, in addition, express FcyRI (CD64).',4 The observed nonspecific PE-CY5 staining pattern was, thus, reminiscent of FcyRI expression. We next assessed binding of PE-CY5 conjugates to PMN and U937 cells cultured overnight with interferon y (IFNy), a condition known to increase FcyRI expression levels.' On both these cells, binding of PE-CY5 conjugates was enhanced (Fig IC, and data (Fig le) . In our experiments, we futher noted both significant batch-to-batch variation in the staining capacity of FcyRI-expressing cells and profound differences between the three commercial suppliers.
Our finding of PE-CY5 binding to FcyRI is consistent with recently observed nonspecific staining of macrophages' and sensitive and specific staining of AML-FAB M3 leukemic cells1o by PE-CY5-conjugated MoAb. In addition, murine FcyRlI and 111 have previously been observed to interact nonspecifically with PE and its conjugates. This characteristic severly limits the use of PE-conjugated antibodies for flow cytometry of murine cells."
We, therefore, wish to alert researchers and clinical immunologistshematologists to the possibility that immunofluorescence stainings of human cells (especially cells from patients treated with G-C S P or I F N y 5 or having acute inflammation'2) bearing FcyRI may not reflect the binding specificity of antibody to antigen, but rather that of PE-CY5 to FcyRI. We noted whole blood staining methods to partially reduce PE-CY5 binding to FcyRI, albeit that stainings of G-CSF-treated patients remained very problematic. We strongly recommend testing of PE-CY5 conjugates for nonspecific binding to FcyRI 
Response: Caveat Emptor
MoAbs have been used to discover and to define a large library of leukocyte differentiation antigen^.'.^ Because of their exquisite specificity, these reagents are powerful tools in research and clinical laboratories. Nevertheless, the use of MoAbs for a specific application has several potential pitfalls. The letter by Van Vugt et al. provides an elegant illustration of one of many problems that may be encountered, and the results emphasize the need for careful quality controls, necessary even when using well-characterized MoAbs, reagent hts, and computerized flow cytometry.
When using antibodies against leukocyte differentiation antigens for immunophenotyping of cell populations, several assumptions concerning the binding specificity of the antibodies must be validated.6 First, the full spectrum of cellular expression of the antigen identified by the given antibodies must be known for the cell population being tested. A given antigen may not be exclusively expressed on the target cell of interest, and display of the antigen by additional cell types can confound conclusions. For example, CD4 is commonly used to identify a subset of T lymphocytes, but is also expressed weakly on monocytes?
In addition, as the letter by Van Vugt et a1 emphasizes, one naturally hopes that the binding of the well-characterized MoAb to cells will occur exclusively via the antibody's unique antigen-binding site located in the F, region of the antibody molecule. However, chemical conjugation of fluorochromes to MoAbs can result in aggregation of antibody molecules, can affect their net charge, or, theoretically, may create new binding sites. For example, overconjugation of antibodies with FITC often results in increased aggregation of the protein molecules. Whereas monomeric IgG molecules bind to cellular F, receptors with low affinity, aggregated IgG binds strongly to F, receptors. Thus, if a given fluorochrome-conjugated MoAb preparation contains large amounts of high molecular weight aggregated fluorochrome-Ig complexes, the preparation will nonspecifically label cells expressing F, receptors for the given Ig species. Use of F(ab')* antibody preparations avoids nonspecific labeling of cellular F, receptors.
Overconjugation of antibodies with FITC also can change the emission spectrum of the dye as a result of dye-dye interactions. This can change the settings needed for fluorescence compensation. PE and related biologic chromophores have increased emission efficiency and can have lower nonspecific staining properties. This is especially true if the antibody-dye coupling uses site-directed conjugation techniques in which only one PE and one IgG molecule form a complex. Other conjugation techniques can produce larger molecular complexes with a resultant increase in nonspecific binding, as discussed above.
Tandem conjugates, especially PE-CY5, have shown significant increased nonspecific binding to both monocytes and granulocytes since their first
The letter by Van Vught et a1 elucidates the mechanism of this binding through CD64 (F,RI). The techniques used for conjugation of these multiple chromophore dyes may result not only in differences in nonspecificity, but also in the efficiency of energy transfer. Differences in dye-dye interactions can affect the amount of primary dye emission that is not quenched by the acceptor molecule. An alternative far red emitting dye that can be used with an argon ion laser, peridinium chlorophyll protein complex (Peep), is quenched by high power lasers (>50 mw) limiting P e e p utility primarily to bench top flow cytometers with low power lasers.
Thus, among other problems, conjugation of a fluorochrome to an antibody can reduce the specificity of a reagent, resulting from differences between the chemical structure of the antibody-fluorochrome complex and that of the native antibody. The use of an isotype-matched MoAb as a control may be necessary but insufficient to control for these changes. The magnitude and significance of all these problems vary, dependent on target cell population, MoAb, conjugation protocol, and from supplier to supplier and lot to lot. These same considerations pertain to secondary antibodies as well as to the primary MoAb. In general, cell labeling using direct MoAb-fluorochrome conjugates leads to reduced signal, but also has decreased nonspecific binding as compared with two-step (indirect) immunofluorescence.
Because MoAbs are used for a wide variety of purposes and because they are sold at lower prices, the performance of the ideal quality controls for every purpose may not be accomplished by the commercial supplier. Ideally, antibody preparations are tested by the investigator before their use in the intended assay system. The investigator or clinical laboratory must check each lot of conjugated antibody prepared or purchased to assess titer and specificity. One simple antibody specificity-testing approach that is applicable to many intended uses in flow cytometry is to test the binding of the new reagent to CD45-labeled blood or bone marrow cells.'" The intensity of CD45 staining in combination with cellular light scattering can (partially) define multiple lineages of human leukocytes, providing a simple means to determine which cells are labeled with a new reagent, as compared with the authentic old reagent.
These and other limitations of MoAbs as reagents must be controlled for in each experiment or clinical assay, especially when working with cells expressing F, receptors! Let the buyer (and the reviewer and the reader) beware!
